Document is current
Any future updates will be listed below
-
Authors
Sheehan, Gabriel T.
Twardus, Shaina W.
Cagan, Andrew
Ananthakrishnan, Ashwin N.
- License Information
-
More Information
Article History
Received: 15 March 2022
Accepted: 20 April 2022
First Online: 17 May 2022
Declarations
:
: Ananthakrishnan has served on the scientific advisory boards of Gilead, Ikena therapeutics, and Sun Pharma. Ananthakrishnan is supported by grants from the National Institutes of Health, Crohn’s and Colitis Foundation, and Chleck Family Foundation. The other authors have no conflict of interest to disclose.
